Phuturdex › Diseases › Eye disease
Drugs in development · updated 30 October 2026
Eye disease: drugs in development
As of 30 October 2026 there are 23 active clinical trials (recruiting or ongoing, phases I–III) on 19 drugs for eye disease. 14 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Sepofarsen | II–III | 2 | NCT03913143 |
| Fusidic Acid | III | 1 | NCT06911424 |
| Linsitinib | II–III | 1 | NCT06112340 |
| ADVM-022 | II | 1 | NCT05536973 |
| GS010 | II | 1 | NCT07303296 |
| OCT-980 | I–II | 1 | NCT07408232 |
| QR-1123 | I–II | 1 | NCT04123626 |
| SPVN06 | I–II | 1 | NCT05748873 |
| SPVN20 | I–II | 1 | NCT07807111 |
| TOUR006 - | II | 1 | NCT06088979 |
| VG801 | I–II | 1 | NCT07002398 |
| ETHY-001 | I | 1 | NCT07885605 |
| VG901 | I | 1 | NCT06291935 |
| IVB102 | Early I | 1 | NCT06289452 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AfliberceptEYLEA Injection, Ziv-Aflibercept | III | 4 | NCT07482176 |
| AtropineAtropine (Autoinjector)®, Isopto Atropine® | III | 1 | NCT07028827 |
| RanibizumabLucentis, Ranluspec® | II–III | 1 | NCT04704921 |
| DapagliflozinForxiga, Dapagliflozin Propanediol | II | 1 | NCT07174687 |
| EMLA SPRAY | I–II | 1 | NCT05694858 |
Sorted by most advanced phase and number of active trials.
All 19 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Uveal melanoma 49 drugs
- Macular degeneration 40 drugs
- Sjogren's Syndrome 29 drugs
- Graves' ophthalmopathy 19 drugs
- Neuromyelitis optica 25 drugs
- Melanoma 352 drugs
- Retinitis pigmentosa 25 drugs
- Geographic atrophy 26 drugs
- Diabetic retinopathy 17 drugs
- Myopia 5 drugs
- Stargardt disease 14 drugs
- Systemic lupus erythematosus 178 drugs
Broader categories
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Hereditary eye disease 4 drugs
- Genetic disease 33 drugs
- Nervous System Diseases 39 drugs
- Retinal degeneration 15 drugs
- Neurologic Manifestations 15 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D005128 “Eye Diseases”.